Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
ROCKVILLE, Md., Nov. 07, 2016 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investor meetings at the following three conferences:
Stifel 2016 Healthcare Conference
Date: Tuesday, November 15, 2016
Time: 10:15 a.m. EST
Place: Lotte New York Palace Hotel, New York
Jefferies London Healthcare Conference
Date: Thursday, November 17, 2016
Time: 3:20 p.m. GMT (10:20 p.m. EST)
Place: Waldorf Hilton, London, U.K.
Piper Jaffray 28th Annual Healthcare Conference
Date: Tuesday, November 29, 2016
Time: 9:00 p.m. EST
Place: Lotte New York Palace Hotel, New York
Investors interested in arranging a meeting with the Company's management during these conferences should contact the conference coordinator.
A live webcast of the presentations can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company's website at www.supernus.com. An archived replay of these webcasts will be available for 60 days on the Company's website after each conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in patients with ADHD and SPN-812 for the treatment of ADHD.
CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 Or Investor Contact: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: [email protected]
